Citius Oncology
CTOR
6 hedge funds and large institutions have $97.7K invested in Citius Oncology in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.13% less ownership
Funds ownership: 0.28% → 0.15% (-0.13%)
45% less funds holding
Funds holding: 11 → 6 (-5)
58% less capital invested
Capital invested by funds: $230K → $97.7K (-$133K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$26.7K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$78K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$26.1K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$24.3K |
| 4 |
Renaissance Technologies
New York
|
-$12.9K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$5.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $46.3K | +$26.7K | +24,940 | +101% |
|
|
IA
2
IFP Advisors
Tampa,
Florida
| $20.7K | – | – | – |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $19.1K | +$8.45K | +7,888 | +62% |
|
|
YCM
4
Yakira Capital Management
Westport,
Connecticut
| $11.2K | – | – | – |
|
|
5
Osaic Holdings
Scottsdale,
Arizona
| $325 | -$5.5K | -5,130 | -94% |
|
6
Bank of America
Charlotte,
North Carolina
| $149 | – | – | – |
|
|
HF
7
HRT Financial
New York
| – | -$78K | -68,543 | Closed |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$26.1K | -22,699 | Closed |
|
|
XT
9
XTX Topco
George Town,
Cayman Islands
| – | -$24.3K | -21,095 | Closed |
|
|
10
Renaissance Technologies
New York
| – | -$12.9K | -11,196 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$47 | -41 | Closed |
|
CTOR Hedge Fund Activity: Q1 2025 in Review
6 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q1 2025, worth a combined $97.7K — down 58% from $230K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CTOR and 0 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $26.7K. The largest seller was HRT Financial, exiting entirely with an estimated $78K sold.
- 6 institutional investors held Citius Oncology (CTOR) as of Q1 2025, down from 11 in Q4 2024.
- Funds reported $97.7K of Citius Oncology stock for Q1 2025, down 58% quarter-over-quarter.
- 0 funds opened new Citius Oncology positions in Q1 2025 and 5 closed out, a net change of -5 holders.
- The largest Citius Oncology buyer in Q1 2025 was UBS Group, an estimated $26.7K added.
- The largest Citius Oncology seller in Q1 2025 was HRT Financial, an estimated $78K sold.
Based on aggregated 13F filings for Q1 2025.